What is the recommended dosing and monitoring of Entresto (sacubitril/valsartan) in adults with heart failure with reduced ejection fraction who have low estimated glomerular filtration rate (eGFR)?

Entresto in Low GFR

Entresto (sacubitril/valsartan) can be safely initiated and continued in patients with heart failure with reduced ejection fraction (HFrEF) even when eGFR declines below 30 mL/min/1.73 m², with dose adjustment required for severe renal impairment at initiation.

Dosing Strategy Based on Renal Function

For eGFR ≥30 mL/min/1.73 m²

• Standard initiation: Start at 49/51 mg twice daily 1
• Target dose: Titrate to 97/103 mg twice daily over 2-4 weeks as tolerated 1
• Follow standard escalation protocol

For Severe Renal Impairment (eGFR <30 mL/min/1.73 m²)

• Reduced starting dose: Begin at 24/26 mg twice daily (half the standard starting dose) 1
• Slower titration: Increase every 2-4 weeks based on tolerability
• Target: Aim for 97/103 mg twice daily if tolerated, though lower maintenance doses are acceptable

For Patients on Dialysis

• Contraindicated per FDA labeling 1

Evidence Supporting Use in Low eGFR

The most compelling recent evidence comes from a 2024 post-hoc analysis of PARADIGM-HF and PARAGON-HF trials 2. This study demonstrated:

• 691 patients (8.3%) in PARADIGM-HF and 613 patients (12.9%) in PARAGON-HF experienced eGFR decline to <30 mL/min/1.73 m² during follow-up
• Continued benefit: Sacubitril/valsartan maintained superiority over ACE inhibitors/ARBs for the primary outcome (cardiovascular death and HF hospitalization) regardless of eGFR deterioration (P-interaction = 0.50 in PARADIGM-HF, 0.64 in PARAGON-HF) 2
• Safety profile: No incremental safety risk with continuation despite higher baseline risk in this population 2
• Key finding: Patients who remained on treatment showed similar safety profiles between treatment groups 2

This represents the highest quality, most recent evidence directly addressing your question and strongly supports continuation of therapy even when eGFR falls below 30 mL/min/1.73 m².

Monitoring Requirements

Initial Phase (First 2-4 Weeks)

• Blood pressure: Check 1-2 weeks after each dose increment
• Renal function: Measure serum creatinine and eGFR at 1-2 weeks, then at 3 months 3, 4
• Electrolytes: Monitor potassium closely, especially with concomitant MRA use
• Watch for: Symptomatic hypotension, hyperkalemia, acute kidney injury

Maintenance Phase

• Every 6 months: Blood pressure, renal function, electrolytes 3, 4
• More frequent monitoring if eGFR <30 mL/min/1.73 m² or declining

Critical Safety Considerations

Hyperkalemia Risk

• Higher incidence in patients with renal dysfunction (16.3% vs 6.5% in those without RD) 5
• Avoid potassium-sparing diuretics during initiation 3, 4
• If K+ >5.0 mEq/L: Hold therapy until <5.0 mEq/L, then restart at reduced dose 6
• Avoid NSAIDs which worsen renal function and increase hyperkalemia risk 3, 4

Hypotension

• More common in renal dysfunction patients 5
• Start at lower dose (24/26 mg BID) if systolic BP <100 mmHg or patient not on prior ACE-I/ARB 1
• Consider evening dosing to minimize symptomatic hypotension 3, 4

Renal Function Deterioration

• Expect transient eGFR decline: The TRANSITION study showed eGFR actually improved by 4.1 mL/min/1.73 m² in patients with baseline RD (eGFR 30-60) 5
• Do not discontinue for modest creatinine elevation unless substantial deterioration occurs 3, 4
• Renal impairment events: 6.4% in RD group vs 2.1% without RD 5

Triple RAAS Blockade Warning

• Never combine Entresto with ACE-I + MRA due to excessive hyperkalemia and renal dysfunction risk 7
• 36-hour washout required when switching from ACE-I to Entresto 1

Clinical Benefits in Renal Dysfunction

Despite concerns, evidence shows:

1. Renal protective effects: Sacubitril/valsartan demonstrates renal protection, particularly in patients with eGFR ≥60 mL/min/1.73 m² 8
2. Improved cardiac biomarkers: NT-proBNP reduced by 28.6% in RD patients (though less than the 44.8% in non-RD patients) 5
3. Mortality benefit maintained: The 20% reduction in cardiovascular death and HF hospitalization persists across renal function categories 2, 9

Guideline Recommendations

The 2016 ESC Guidelines 7 and 2022 AHA/ACC/HFSA Guidelines 10 provide Class I, Level B recommendations for sacubitril/valsartan as replacement for ACE-I in symptomatic HFrEF patients on optimal therapy. While older guidelines don't specifically address low eGFR thresholds, the 2024 research evidence supersedes historical eGFR <30 contraindications 2.

Common Pitfalls to Avoid

1. Premature discontinuation: Don't stop therapy for eGFR <30 unless on dialysis or acute kidney injury develops
2. Inadequate washout: Always allow 36 hours between ACE-I and Entresto to prevent angioedema
3. Aggressive initial dosing: Use 24/26 mg BID starting dose in severe renal impairment
4. Ignoring drug interactions: Stop NSAIDs, avoid triple RAAS blockade
5. Insufficient monitoring: Increase monitoring frequency as eGFR declines

Bottom Line Algorithm

For patients with HFrEF and low eGFR:

• eGFR 30-60: Standard dosing (49/51 mg BID → 97/103 mg BID)
• eGFR <30 (not on dialysis): Start 24/26 mg BID, titrate cautiously to target
• eGFR decline to <30 while on therapy: Continue treatment with close monitoring
• Dialysis: Contraindicated

The evidence strongly supports that continuation of sacubitril/valsartan provides persistent cardiovascular benefit without incremental safety risk, even when eGFR falls below 30 mL/min/1.73 m² 2.